关注
Saad Z. Usmani
Saad Z. Usmani
Chief of Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY
在 mskcc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
50652014
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
25432016
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ...
New England Journal of Medicine 375 (14), 1319-1331, 2016
15982016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ...
The Lancet 387 (10027), 1551-1560, 2016
9822016
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 …
JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ...
The Lancet 398 (10297), 314-324, 2021
9762021
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016
9572016
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ...
New England Journal of Medicine 380 (22), 2104-2115, 2019
8882019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ...
The lancet oncology 21 (2), 207-221, 2020
7252020
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ...
Leukemia 33 (9), 2266-2275, 2019
5152019
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ...
Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016
5022016
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ...
The lancet oncology 18 (4), e206-e217, 2017
4902017
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ...
New England Journal of Medicine 387 (6), 495-505, 2022
4852022
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
4402016
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ...
Leukemia 27 (4), 780-791, 2013
4262013
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
SZ Usmani, C Heuck, A Mitchell, J Szymonifka, B Nair, A Hoering, ...
haematologica 97 (11), 1761, 2012
4222012
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement
MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ...
Journal of Clinical Oncology 33 (6), 657-664, 2015
4202015
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ...
The lancet oncology 20 (6), e302-e312, 2019
3882019
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised …
M Dimopoulos, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ...
The Lancet 396 (10245), 186-197, 2020
3852020
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
N Shah, A Chari, E Scott, K Mezzi, SZ Usmani
Leukemia 34 (4), 985-1005, 2020
3562020
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, ...
The lancet oncology 15 (3), 333-342, 2014
3362014
系统目前无法执行此操作,请稍后再试。
文章 1–20